Korean J Pediatr Hematol Oncol.  1997 Apr;4(1):150-154.

An Autoplex Treatment in a Hemophilia A Patient with High Titer of Anticoagulant FVIII Antibody

• Jeong JH
• Choi YM

Abstract

Hemophilia A is a bleeding disorder resulting from a congenital deficiency of factor VIII. The mainstay of successful hemophilia therapy for either treatment or prevention of acute hemorrage is prompt and sufficient intravenous replacement of factor VIII to hemostatic levels. One of the most serious complications of hemophilia and its therapy is the development of polyclonal antibodies to factor VIII that neutralize factor coagulant activity. APCCs is otherwise known as bypass therapy, products that bypass the requirement for factor VIII for clot formation and moderately effective in controlling bleeding in high inhibitor patients. We experienced a case of hemophilia A with high inhibitor titer in a 13 year-old boy who presented with incarcerated right inguinal hernia and a successful therapeutic effect of APCCs(Autoplex) for controlling post-operative hemorrhages.

Keyword

Hemophilia A; High-inhibitor; APCCs(Autoplex)

MeSH Terms

Adolescent
Antibodies
Factor VIII
Hemophilia A*
Hemorrhage
Hernia, Inguinal
Humans
Male
Antibodies
Factor VIII